Isolation of a high‐affinity Bet v 1‐specific IgG‐derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments

BACKGROUND: Recombinant hypoallergenic allergen derivatives have been used in clinical immunotherapy studies, and clinical efficacy seems to be related to the induction of blocking IgG antibodies recognizing the wild‐type allergens. However, so far no treatment‐induced IgG antibodies have been chara...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Allergy
Main Authors: Gadermaier, E., Marth, K., Lupinek, C., Campana, R., Hofer, G., Blatt, K., Smiljkovic, D., Roder, U., Focke‐Tejkl, M., Vrtala, S., Keller, W., Valent, P., Valenta, R., Flicker, S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
ORIGINAL ARTICLES
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6032869/
https://ncbi.nlm.nih.gov/pubmed/29315611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.13394
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados